Le CompaGnon Part 2

Le CompaGnon Part 2
Wednesday June 22, 2016

From the  American Society of  Clinical  Oncology (ASCO)              

  1. Checkpoint inhibitors
  2. the CAR T Approach
  3. Adoptive cell therapy
  4. Oncolytic virus therapy
  5. Therapeutic vaccines
  6. Cytokines.

Le CompaGnon Part 1 dealt with:

- The two firms, MERK and BMY, who were the first to get approvals of their checkpoint inhibitors. These two . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.